NYSE:NVRO - New York Stock Exchange, Inc. - US64157F1030 - Common Stock - Currency: USD
5.73
+0.02 (+0.35%)
The current stock price of NVRO is 5.73 USD. In the past month the price increased by 16.94%. In the past year, price decreased by -62.55%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABT | ABBOTT LABORATORIES | 28.52 | 230.98B | ||
ISRG | INTUITIVE SURGICAL INC | 82.75 | 216.34B | ||
BSX | BOSTON SCIENTIFIC CORP | 41.98 | 155.28B | ||
SYK | STRYKER CORP | 31.7 | 147.31B | ||
MDT | MEDTRONIC PLC | 16.47 | 112.76B | ||
BDX | BECTON DICKINSON AND CO | 16.39 | 65.45B | ||
EW | EDWARDS LIFESCIENCES CORP | 28.52 | 44.06B | ||
GEHC | GE HEALTHCARE TECHNOLOGY | 20.51 | 42.07B | ||
IDXX | IDEXX LABORATORIES INC | 40.25 | 37.08B | ||
DXCM | DEXCOM INC | 54.15 | 34.90B | ||
RMD | RESMED INC | 26.33 | 34.19B | ||
PHG | KONINKLIJKE PHILIPS NVR- NY | 17.14 | 23.53B |
Nevro Corp. engages in the development of medical devices. The company is headquartered in Redwood City, California and currently employs 1,215 full-time employees. The company went IPO on 2014-11-06. The firm is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. The company has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.
NEVRO CORP
1800 Bridge Parkway
Redwood City CALIFORNIA 94065 US
CEO: D. Keith Grossman
Employees: 1215
Company Website: https://www.nevro.com
Investor Relations: https://nevro.com/English/us/investors/
Phone: 16502510005
The current stock price of NVRO is 5.73 USD. The price increased by 0.35% in the last trading session.
The exchange symbol of NEVRO CORP is NVRO and it is listed on the New York Stock Exchange, Inc. exchange.
NVRO stock is listed on the New York Stock Exchange, Inc. exchange.
22 analysts have analysed NVRO and the average price target is 7.86 USD. This implies a price increase of 37.21% is expected in the next year compared to the current price of 5.73. Check the NEVRO CORP stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NEVRO CORP (NVRO) has a market capitalization of 216.94M USD. This makes NVRO a Micro Cap stock.
NEVRO CORP (NVRO) currently has 1215 employees.
NEVRO CORP (NVRO) has a support level at 5.72 and a resistance level at 5.74. Check the full technical report for a detailed analysis of NVRO support and resistance levels.
The Revenue of NEVRO CORP (NVRO) is expected to decline by -4.09% in the next year. Check the estimates tab for more information on the NVRO EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
NVRO does not pay a dividend.
NEVRO CORP (NVRO) will report earnings on 2025-03-04, after the market close.
NEVRO CORP (NVRO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.77).
The outstanding short interest for NEVRO CORP (NVRO) is 8.03% of its float. Check the ownership tab for more information on the NVRO short interest.
ChartMill assigns a technical rating of 5 / 10 to NVRO. When comparing the yearly performance of all stocks, NVRO is a bad performer in the overall market: 84.88% of all stocks are doing better.
ChartMill assigns a fundamental rating of 2 / 10 to NVRO. NVRO has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months NVRO reported a non-GAAP Earnings per Share(EPS) of -1.77. The EPS increased by 38.11% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -11.64% | ||
ROE | -25.33% | ||
Debt/Equity | 0.81 |
ChartMill assigns a Buy % Consensus number of 50% to NVRO. The Buy consensus is the average rating of analysts ratings from 22 analysts.
For the next year, analysts expect an EPS growth of 3.89% and a revenue growth -4.09% for NVRO